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cyclophosphamide had any beneficial effect in the treatment of lupus nephritis. It would seem unjustifiable, therefore, to continue its use in this condition.
In other autoimmune conditions and malignant disease we suggest carefully controlled trials of cyclophosphamide, assessing its benefits in each condition, and taking into account the long-term risks before it is accepted as standard treatment. Follow-up of patients who have already received the drug should be of long duration.
Symptoms of cystitis-frequency and dysuria, with or without haematuria or bacteriuria-should be taken seriously, as they are common presenting features of carcinoma of the bladder and assume even more importance in patients who have received cyclophosphamide. A skeleton regimen with individual variations would include sixmonthly visits with urological history, urine microscopy, culture, and cytology. If there is a positive response intravenous urography should be performed and, when indicated, cystoscopy. The patient should be advised not to await the next six-monthly appointment if symptoms develop but to report at the earliest opportunity. ' 
Patients, methods, and results
A total of 106 patients with Crohn's disease (mean age 41 years) and 106 patients with ulcerative colitis (mean age 46 years) who were unselected and attending a gastrointestinal clinic were studied; diagnoses were based on conventional criteria. A control group comprised 106 healthy subjects, mainly hospital employees, matched for age and sex with the patients with Crohn's disease. In all subjects anthropometric measurements were made of height, weight, mid-arm circumference (MAC), triceps skinfold thickness (TSF), and total skinfold thickness at four sites (triceps, biceps, subscapular, and suprailiac). Mid-arm muscle circumference (MAMC) was calculated from the formula MAMC=MAC-0-314 TSF.' Observed measurements were expressed as a percentage of ideal standards with the exception of total skinfold thickness, which was expressed in mm. Current smoking habits were documented in all subjects and clinical features of the disease in patients with inflammatory bowel disease.
Non-smokers in the control group and the group with ulcerative colitis were heavier than cigarette smokers and had more subcutaneous fat as determined by skinfold thickness (significant for triceps skinfold thickness in controls (p < 0-05) (table). The difference in measurements between smokers and non-smokers, however, was not evident in the patients with Crohn's disease, except that total skinfold thickness was significantly increased in cigarette smokers compared with non-smokers (p <005). Non-smokers with Crohn's disease had significantly lower values for all measurements than non-smokers in the control group and group with ulcerative colitis; these last two groups showed no difference in measurement. Although most of the measurements in cigarette smokers with Crohn's disease were lower than those in cigarette smokers in the control group and the group with colitis, none of the differences achieved significance.
Mean ± SD anthropometric measurements in non-smokers and cigarette smokers with Crohn's disease and ulcerative colitis, and in controls Mid-arm circumference (% ideal)
93-2±12-7* 987 ± 9-5 100-9 ± 11-7
Triceps skinfold thickness (% ideal) 95-4±43-6* 123-0±31-6 116-2±41-4 Total skinfold thickness (mm) 
Comment
Non-smokers with Crohn's disease had significantly reduced weight, muscle bulk, and adipose tissue compared with non-smokers in the control group and the group with ulcerative colitis. The significance, however, disappeared when cigarette smokers in the three groups were compared, though little reliance can be placed on the small group of smokers with ulcerative colitis. Although non-smokers in the control group and the group with ulcerative colitis followed the recognised pattern of being heavier and fatter than cigarette smokers, this was not found in the patients with Crohn's disease. The reason for this apparent discrepancy is not obvious. Both smokers and nonsmokers with Crohn's disease were well matched in terms of disease activity, disease distribution, steroid treatment, and previous surgical resection. Anorexia and impaired food consumption are important factors in producing nutritional depletion in active Crohn's disease., Most reports agree that smoking reduces hunger,5 and one explanation of our findings may be that patients who already have anorexia due to active disease are relatively unaffected by the additional influence of smoking.
The results emphasise that patients with Crohn's disease are undernourished compared with a healthy population, and conversely that patients with ulcerative colitis are well nourished. They also highlight the importance of smoking habits in any nutritional study.
